Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study

被引：0
|
作者：
Rimassa, L. [1 ]
Bridgewater, J. A. [2 ]
Casadei-Gardini, A. [3 ]
Wilmink, H. [4 ]
Sim, H-W [5 ,6 ,7 ]
de Vos-Geelen, J. [8 ]
Mercade, T. Macarulla [9 ]
Malka, D. [10 ]
Gharbi, H. [11 ]
Robert, R. [11 ]
Sullivan, A. [12 ]
Vogel, A. [13 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] UCL Canc Inst, Dept Med Oncol, Paul OGorman Bldg, London, England
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst Hosp, Dept Oncol, Milan, Italy
[4] Locatie Acad Med Ctr AMC, Amsterdam Univ Med Ctr UMC, Med Oncol, Amsterdam, Netherlands
[5] Kinghorn Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
[6] Univ New South Wales, Fac Med & Hlth, Sydney, NSW, Australia
[7] Univ Sydney, NHMRC Clin Trials Ctr, Darlinghurst, NSW, Australia
[8] Maastricht Univ Med Ctr MUMC, Dept Internal Med, Div Med Oncol, Maastricht, Netherlands
[9] VHIO Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain
[10] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[11] Servier, Global Med & Patient Affairs, Suresnes, France
[12] Servier Pharmaceut, Global Biometr, Boston, MA USA
[13] MHH, Hepatol Oncol, Hannover, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.159
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138MO
引用
收藏
页码：S1457 / S1457
页数：1
相关论文
共 50 条
  • [41] Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
    Zhu, Andrew X.
    Macarulla, Teresa
    Javle, Milind M.
    Kelley, R. Kate
    Lubner, Sam J.
    Adeva, Jorge
    Cleary, James M.
    Catenacci, Daniel V. T.
    Borad, Mitesh J.
    Bridgewater, John A.
    Harris, William P.
    Murphy, Adrian G.
    Oh, Do-Youn
    Whisenant, Jonathan R.
    Lowery, Maeve A.
    Goyal, Lipika
    Shroff, Rachna T.
    El-Khoueiry, Anthony B.
    Chamberlain, Christina X.
    Aguado-Fraile, Elia
    Choe, Sung
    Wu, Bin
    Liu, Hua
    Gliser, Camelia
    Pandya, Shuchi S.
    Valle, Juan W.
    Abou-Alfa, Ghassan K.
    JAMA ONCOLOGY, 2021, 7 (11) : 1669 - 1677
  • [42] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
    Mellinghoff, Ingo
    Penas-Prado, Marta
    Peters, Katherine
    Cloughesy, Timothy
    Burris, Howard
    Maher, Elizabeth
    Janku, Filip
    Cote, Gregory
    De La Fuente, Macarena
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Xu, Huansheng
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi
    Wen, Patrick
    NEURO-ONCOLOGY, 2018, 20 : 18 - 18
  • [43] SAMELISANT: BASELINE CHARACTERISTICS FROM A PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY IN PATIENTS WITH NARCOLEPSY
    Nirogi, Ramakrishna
    Ravula, Jyothsna
    Jayarajan, Pradeep
    Jetta, Satish
    Bhyrapuneni, Gopinadh
    Benade, Vijay
    Shinde, Anil
    Goyal, Vinod
    SLEEP, 2021, 44 : A199 - A199
  • [44] Safety and tolerability of Rebif® New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis:: results from a phase IIIb study
    Giovannoni, G.
    Barbarash, O.
    Casset-Semanaz, F.
    King, J.
    Metz, L.
    Pardo, G.
    Simsarian, J.
    Sorensen, P. Soelberg
    Stubinski, B.
    JOURNAL OF NEUROLOGY, 2008, 255 : 178 - 178
  • [45] Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
    Lebbe, C.
    Meyer, N.
    Mortier, L.
    Marquez-Rodas, I.
    Robert, C.
    Rutkowski, P.
    Menzies, A. M.
    Eigentler, T.
    Ascierto, P. A.
    Smylie, M.
    Ajaz, M.
    Svane, I-M.
    Gonzalez, R.
    Rollin, L.
    Saci, A.
    Grigoryeva, E.
    Pigozzo, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 737 - 737
  • [46] Baseline demographics and disease characteristics of patients with episodic cluster headache: results from a phase 3 clinical trial
    Martinez, James M.
    Bardos, Jennifer N.
    Oakes, Tina M. Myers
    Zhou, Chunmei
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [47] Safety and Efficacy of RIX-FP in Patients With Hemophilia B: Interim Results From A Phase IIIB Extension Study
    Santagostino, E.
    St Ledger, K.
    Veldman, A.
    Li, Y.
    Strelecki, M.
    Cole, G.
    Blackman, N.
    HAEMOPHILIA, 2017, 23 : 55 - 56
  • [48] Maintenance with rituximab is not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIB MAXIMA study
    Witzens-Harig, M.
    Di Rocco, A.
    van Hazel, G.
    Chamone, D.
    Ruffert, K.
    Rowe, J.
    Arcaini, L.
    Poddubnaya, I.
    Ho, A.
    Ivanova, V.
    Vranowsky, A.
    Oertel, S.
    Thurley, D.
    Foa, R.
    ONKOLOGIE, 2012, 35 : 46 - 46
  • [49] Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study
    Sehouli, Jalid
    Wimberger, Pauline
    Vergote, Ignace B.
    Rosenberg, Per
    Schneeweiss, Andreas
    Bokemeyer, Carsten
    Salat, Christoph
    Scambia, Giovanni
    Berton-Rigaud, Dominique
    Siena, Salvatore
    Santoro, Armando
    Cervantes-Ruiperez, Andres
    Guastalla, Jean Paul
    Tournigand, Christophe
    Colombo, Nicoletta
    Dudnitchenko, Alexander Serg
    Bondar, Vladimir
    Westermann, A. M.
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma
    Chesney, Jason
    Awasthi, Sanjay
    Curti, Brendan
    Hutchins, Laura
    Linette, Gerald
    Triozzi, Pierre
    Tan, Marcus C. B.
    Brown, Russell E.
    Nemunaitis, John
    Whitman, Eric
    Windham, Christopher
    Lutzky, Jose
    Downey, Gerald F.
    Batty, Nicolas
    Amatruda, Thomas
    MELANOMA RESEARCH, 2018, 28 (01) : 44 - 51
12345